Stocks to watch today include Maruti Suzuki

Indian equity benchmark indices posted mild gains on Friday, despite profit booking at higher levels as positive Q1 earnings by India Inc supported the sentiments amid inflation fears. The BSE Sensex rose 166.49 points, or 0.21 per cent, to close at 78,094.64, while NSE’s Nifty50 gained 66.45 points, or 0.27 per cent, to end at 24,383.60.

Several stocks may remain under spotlight before the opening bell on Monday, August 03, 2026, including those that will announce their quarterly results today, such as SBI Funds Management, DLF, and Escorts Kubota.

ITC, the FMCG and cigarette major, reported a 27.1 per cent year-on-year fall in net profit to Rs 3,578.8 crore, while revenue dropped 14.4 per cent to Rs 16,907.6 crore for the June 2026 quarter. They had EBITDA of Rs 4,514 crore, with margins contracted to 26.7 per cent for the reported quarter.

Maruti Suzuki India, the country’s largest carmaker, reported a 10.8 per cent decline in net profit to Rs 3,352.1 crore for the June 2026 quarter, despite a robust 35.9 per cent rise in revenue to Rs 52,455.7 crore. The company had EBITDA margins of 8.2 per cent, while total vehicle sales surged 33.7 per cent to 2.41 lakh units.

Related: UK passive funds dominate Q2 investor inflows

Mahindra & Mahindra, the automaker, reported a 25.8 per cent rise in total automotive sales to 1,03,860 units in July. The company’s domestic passenger vehicle sales increased 20.4 per cent to 60,048 units, while tractor sales climbed 20 per cent to 34,420 units.

Hero MotoCorp, India’s largest two-wheeler maker, reported an 18.6 per cent increase in total sales to 5.33 lakh units in July. Domestic sales rose 21.6 per cent to 5.01 lakh units, while exports declined 14.3 per cent to 32,013 units.

Dr Reddy’s Laboratories, the pharma major, has received approval from the USFDA for Rituximab, a biosimilar to Rituxan, for the US market. This approval is for treating several B-cell malignancies, including non-Hodgkin lymphoma and chronic lymphocytic leukemia, as well as certain autoimmune conditions.

Lupin, the drugmaker company, has received approval under the Federal Food, Drug, and Cosmetic Act for Diazepam Injection USP, 10 mg/2 mL (5 mg/mL), in single-dose prefilled syringes.

Companies are focusing on expanding their product portfolios and increasing their presence in the global market. This trend is expected to continue, driven by the growing demand for affordable and effective treatments through job growth in related sectors.

Related: Adviser faces conflict of interest at home

Divi’s Laboratories, the pharma company, posted a 65.5 per cent jump in net profit to Rs 902 crore, while revenue increased 27.8 per cent to Rs 3,080 crore in the June 2026 quarter. The company had EBITDA of Rs 1,255 crore, with EBITDA margins expanding to 40.8 per cent.

Bharat Electronics, the state-run defence player, has secured additional orders worth Rs 847 crore since July 13. The major orders include electro-optics, a security operations centre, seekers, components, spares, and services.

Indian Oil Corporation reported a net loss of Rs 2,661.3 crore for the June 2026 quarter against a profit of Rs 5,688.6 crore in the year-ago period. Revenue, excluding excise duty, rose 36 per cent to Rs 2.62 lakh crore. EBITDA declined sharply to Rs 1,947 crore, with margins shrinking to 1 per cent, although domestic fuel sales improved to 25.25 million tonnes.

Coal India reported an 8.4 per cent increase in coal production to 50.4 million tonnes in July, while coal offtake rose 17.4 per cent to 63.7 MT.